The DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.
Permissive Secondary Mutations Enable the Evolution of Influenza Oseltamivir Resistance
Open accessAbstract
Influenza Escape Tricks: Tamiflu, or oseltamivir, has been extensively stockpiled by several governments in anticipation of a dangerous influenza pandemic. So far, its large-scale use has not been required, but, despite this, resistance has emerged in seasonal strains mediated by a single point mutation of histidine to tyrosine in the 274 residue (H274Y) of neuraminidase. When the resistant virus was first discovered in 1998, it grew poorly, but by 2008 the virus was reinvigorated and the mutation had spread worldwide in seasonal influenza. So what happened that improved viral fitness so radically? Bloom et al. (p. 1272 ; see the Perspective by Holmes ) show that the H274Y mutation hinders the folding of the neuraminidase enzyme. In the more vigorous recent oseltamivir-resistant isolates, other mutations compensate for the deleterious effect of H274Y and restore fitness to the virus.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Pushko, P., Pumpens, P., & Grens, E. (2013) · Intervirology · doi:10.1159/000346773 · Cited by 5,950
Updating the accounts: global mortality of the 1918–1920 "Spanish" influenza pandemic.
Johnson, N. P. A. S., & Mueller, J. (2002) · Bulletin of the History of Medicine · doi:10.1353/bhm.2002.0022 · Cited by 1,980
Protein stability promotes evolvability
Bloom, J. D., Labthavikul, S. T., Otey, C. R., & Arnold, F. H. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0510098103 · Cited by 1,211
Self-citationNeuraminidase Inhibitors for Influenza
Moscona, A. (2005) · New England Journal of Medicine · doi:10.1056/nejmra050740 · Cited by 1,094
The genomic and epidemiological dynamics of human influenza A virus
Rambaut, A., Pybus, O. G., Nelson, M. I., Viboud, C., Taubenberger, J. K., & Holmes, E. C. (2008) · Nature · doi:10.1038/nature06945 · Cited by 925
The structure of H5N1 avian influenza neuraminidase suggests new opportunities for drug design
Russell, R. J., Haire, L. F., Stevens, D. J., Collins, P. J., Lin, Y. P., Blackburn, G. M., Hay, A. J., Gamblin, S. J., & Skehel, J. J. (2006) · Nature · doi:10.1038/nature05114 · Cited by 813
Functional balance between haemagglutinin and neuraminidase in influenza virus infections
Wagner, R., Matrosovich, M., & Klenk, H. (2002) · Reviews in Medical Virology · doi:10.1002/rmv.352 · Cited by 608
Matrosovich, M. N., Matrosovich, T. Y., Gray, T., Roberts, N. A., & Klenk, H.-D. (2004) · Journal of Virology · doi:10.1128/jvi.78.22.12665-12667.2004 · Cited by 606
Crystal structures of oseltamivir-resistant influenza virus neuraminidase mutants
Collins, P. J., Haire, L. F., Lin, Y. P., Liu, J., Russell, R. J., Walker, P. A., Skehel, J. J., Martin, S. R., Hay, A. J., & Gamblin, S. J. (2008) · Nature · doi:10.1038/nature06956 · Cited by 534
Global Transmission of Oseltamivir-Resistant Influenza
Moscona, A. (2009) · New England Journal of Medicine · doi:10.1056/nejmp0900648 · Cited by 469
Cited by
Starr, T. N., Greaney, A. J., Hilton, S. K., Ellis, D., Crawford, K. H. D., Dingens, A. S., Navarro, M. J., Bowen, J. E., Tortorici, M. A., Walls, A. C., et al. (2020) · Cell · doi:10.1016/j.cell.2020.08.012 · Cited by 1,956
“Second, there are a number of RBD mutations that enhance ACE2 affinity, which implies evolutionary potential for compensation of deleterious mutations in the ACE2 interface in a manner reminiscent of multi-step escape pathways that have been described for other viruses (Bloom et al., 2010; Friedrich et al., 2004; Gong…”
Self-citationKrammer, F., Smith, G. J. D., Fouchier, R. A. M., Peiris, M., Kedzierska, K., Doherty, P. C., Palese, P., Shaw, M. L., Treanor, J., Webster, R. G., et al. (2018) · Nature Reviews Disease Primers · doi:10.1038/s41572-018-0002-y · Cited by 1,570
Prospective mapping of viral mutations that escape antibodies used to treat COVID-19
Starr, T. N., Greaney, A. J., Addetia, A., Hannon, W. W., Choudhary, M. C., Dingens, A. S., Li, J. Z., & Bloom, J. D. (2021) · Science · doi:10.1126/science.abf9302 · Cited by 743
“A caveat is that over longer evolutionary timeframes, the space of tolerated mutations could shift due to epistatic interactions, as has been observed in viral immune and drug escape ( 19 – 21 ).”
BackgroundSelf-citationThe evolution of seasonal influenza viruses
Petrova, V. N., & Russell, C. A. (2018) · Nature Reviews Microbiology · doi:10.1038/nrmicro.2017.118 · Cited by 846
Epistasis in protein evolution
Starr, T. N., & Thornton, J. W. (2016) · Protein Science · doi:10.1002/pro.2897 · Cited by 569
Rules of engagement: molecular insights from host–virus arms races
Daugherty, M. D., & Malik, H. S. (2012) · Annual Review of Genetics · doi:10.1146/annurev-genet-110711-155522 · Cited by 515
Global epistasis makes adaptation predictable despite sequence-level stochasticity
Kryazhimskiy, S., Rice, D. P., Jerison, E. R., & Desai, M. M. (2014) · Science · doi:10.1126/science.1250939 · Cited by 492
Drug resistance in influenza A virus: the epidemiology and management
Hussain, M., Galvin, H., Haw, T. Y., Nutsford, A., & Husain, M. (2017) · Infection and Drug Resistance · doi:10.2147/idr.s105473 · Cited by 439
Volz, E. M., Koelle, K., & Bedford, T. (2013) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1002947 · Cited by 417
Integrating influenza antigenic dynamics with molecular evolution
Bedford, T., Suchard, M. A., Lemey, P., Dudas, G., Gregory, V., Hay, A. J., McCauley, J. W., Russell, C. A., Smith, D. J., & Rambaut, A. (2014) · eLife · doi:10.7554/elife.01914 · Cited by 406
Continuing challenges in influenza
Webster, R. G., & Govorkova, E. A. (2014) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.12462 · Cited by 399
Influenza neuraminidase inhibitors: antiviral action and mechanisms of resistance
McKimm‐Breschkin, J. L. (2013) · Influenza and Other Respiratory Viruses · doi:10.1111/irv.12047 · Cited by 390
Currin, A., Swainston, N., Day, P. J., & Kell, D. B. (2015) · Chemical Society Reviews · doi:10.1039/c4cs00351a · Cited by 388
Influenza virus resistance to neuraminidase inhibitors
Samson, M., Pizzorno, A., Abed, Y., & Boivin, G. (2013) · Antiviral Research · doi:10.1016/j.antiviral.2013.03.014 · Cited by 343
Influenza and antiviral resistance: an overview
Lampejo, T. (2020) · European Journal of Clinical Microbiology & Infectious Diseases · doi:10.1007/s10096-020-03840-9 · Cited by 342
Stability-mediated epistasis constrains the evolution of an influenza protein
Gong, L. I., Suchard, M. A., & Bloom, J. D. (2013) · eLife · doi:10.7554/elife.00631 · Cited by 336
Self-citationEvolutionary biochemistry: revealing the historical and physical causes of protein properties
Harms, M. J., & Thornton, J. W. (2013) · Nature Reviews Genetics · doi:10.1038/nrg3540 · Cited by 330
Causes of molecular convergence and parallelism in protein evolution
Storz, J. F. (2016) · Nature Reviews Genetics · doi:10.1038/nrg.2016.11 · Cited by 316
Quadrivalent influenza nanoparticle vaccines induce broad protection
Boyoglu-Barnum, S., Ellis, D., Gillespie, R. A., Hutchinson, G. B., Park, Y.-J., Moin, S. M., Acton, O. J., Ravichandran, R., Murphy, M., Pettie, D., et al. (2021) · Nature · doi:10.1038/s41586-021-03365-x · Cited by 304
The mechanism of resistance to favipiravir in influenza
Goldhill, D. H., te Velthuis, A. J. W., Fletcher, R. A., Langat, P., Zambon, M., Lackenby, A., & Barclay, W. S. (2018) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1811345115 · Cited by 298
The Causes and Consequences of Genetic Interactions (Epistasis)
Domingo, J., Baeza-Centurion, P., & Lehner, B. (2019) · Annual Review of Genomics and Human Genetics · doi:10.1146/annurev-genom-083118-014857 · Cited by 242
Hurt, A. C., Besselaar, T. G., Daniels, R. S., Ermetal, B., Fry, A., Gubareva, L., Huang, W., Lackenby, A., Lee, R. T. C., Lo, J., et al. (2016) · Antiviral Research · doi:10.1016/j.antiviral.2016.06.001 · Cited by 270
Mucin biopolymers as broad-spectrum antiviral agents
Lieleg, O., Lieleg, C., Bloom, J., Buck, C. B., & Ribbeck, K. (2012) · Biomacromolecules · doi:10.1021/bm3001292 · Cited by 167
Self-citationHistorical contingency and its biophysical basis in glucocorticoid receptor evolution
Harms, M. J., & Thornton, J. W. (2014) · Nature · doi:10.1038/nature13410 · Cited by 147
Two-stepping through time: mammals and viruses
Meyerson, N. R., & Sawyer, S. L. (2011) · Trends in Microbiology · doi:10.1016/j.tim.2011.03.006 · Cited by 133
Strauch, E.-M., Bernard, S. M., La, D., Bohn, A. J., Lee, P. S., Anderson, C. E., Nieusma, T., Holstein, C. A., Garcia, N. K., Hooper, K. A., et al. (2017) · Nature Biotechnology · doi:10.1038/nbt.3907 · Cited by 119
“Resistance has evolved to widely used anti-viral drugs 13, 14 , and seasonal vaccines are unlikely to provide much if any protection against newly emerging viruses.”
BackgroundSelf-citationProtein design using structure-based residue preferences
(2024) · doi:10.1038/s41467-024-45621-4 · Cited by 38
Metadata
- Authors
- Bloom, J. D., Gong, L. I., & Baltimore, D.
- Venue
- Science
- Published
- 2010-06-04
- Volume
- 328
- Issue
- 5983
- Pages
- 1272-1275
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- OpenAlex
- W2046094044
- Cited by
- 649
- References
- 29
- FWCI
- 37.53
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.